8-K: Cingulate Inc. Announces Positive Full Year 2024 Results and Advances CTx-1301 Towards NDA Submission

Cingulate Inc. reports positive financial results for 2024, highlighted by increased working capital and progress towards NDA submission for its lead ADHD asset, CTx-1301.

Summary

• Cingulate Inc. announced its financial results for the year ended December 31, 2024, and provided a clinical and business update.
• The company is on track for NDA submission for CTx-1301 in mid-2025, following a pre-NDA meeting with the FDA scheduled for April 2, 2025.
• Safety data from Phase 3 trials of CTx-1301 showed no serious treatment emergent adverse events.
• Cingulate increased its working capital by $17.5 million compared to December 31, 2023, extending its cash runway into Q4 2025.
• The company's cash and cash equivalents as of December 31, 2024, were approximately $12.2 million.
• Research and development expenses were $9.4 million for the year ended December 31, 2024, compared to $15.5 million for the year ended December 31, 2023.
• Net loss was $15.5 million for the year ended December 31, 2024, compared to $23.5 million for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the progress towards NDA submission, positive safety data, and improved financial position. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• The company has a clear timeline for NDA submission of CTx-1301.
• The safety profile of CTx-1301 has been consistent across multiple clinical trials.
• The company has strengthened its balance sheet with a significant increase in working capital.
• The cash runway extends into Q4 2025, beyond the targeted NDA submission date.
• Net loss has decreased year-over-year, indicating improved financial performance.

Negatives

• The company is still operating at a net loss, although it has decreased compared to the previous year.
• R&D expenses have decreased, which may impact future product development.

Risks

• The FDA may not approve the NDA for CTx-1301.
• The company may need to raise additional capital in the future.
• Competition in the ADHD treatment market could impact the commercial success of CTx-1301.

Future Outlook

Cingulate is focused on submitting the NDA for CTx-1301 in mid-2025 and potentially bringing the first true once-daily stimulant medication to treat ADHD to market, assuming FDA approval.

Management Comments

• Cingulate Chairman and CEO Shane J Schaffer stated that the capital raised has allowed the company to strengthen its balance sheet and complete all required clinical trials for NDA submission for CTx-1301.
• He also expressed anticipation for meeting with the FDA and submitting the new drug application this summer.

Industry Context

The announcement highlights Cingulate's progress in the competitive ADHD treatment market, where there is a need for medications with improved duration of action and patient convenience. The company's PTR technology aims to address this need with a once-daily dosing regimen.

Comparison to Industry Standards

• The company is developing CTx-1301, a drug for ADHD, which is a market dominated by companies such as Teva, Novartis (Ritalin), and Shire (now Takeda) with Adderall XR and Vyvanse.
• The company is attempting to create a true once-daily stimulant medication to treat ADHD over the entire active day, which would be a significant improvement over existing extended-release stimulant products that begin to wear off.

Stakeholder Impact

• Shareholders will benefit from the progress towards commercialization of CTx-1301 and the improved financial stability of the company.
• Patients with ADHD may benefit from a new treatment option with a convenient once-daily dosing regimen.

Next Steps

• Attend the in-person pre-NDA meeting with the FDA on April 2, 2025.
• Prepare and submit the NDA for CTx-1301 in mid-2025.
• Continue to explore licensing agreements both inside and outside the United States.

Key Dates

Keywords

CTx-1301, ADHD, NDA submission, clinical trials, financial results, Cingulate, pharmaceutical, working capital, cash runway